These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18018484)

  • 1. Animal models of Parkinson's disease: similarities and differences between the disease and models.
    Hattori N; Sato S
    Neuropathology; 2007 Oct; 27(5):479-83. PubMed ID: 18018484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pathogenesis of Parkinson's disease: a hint from insights of familial Parkinson's disease].
    Hattori N; Kubo S
    Rinsho Shinkeigaku; 2007 Nov; 47(11):774-8. PubMed ID: 18210796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
    Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
    Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease.
    Hattori N; Shimura H; Kubo S; Wang M; Shimizu N; Tanaka K; Mizuno Y
    J Neural Transm Suppl; 2000; (60):101-16. PubMed ID: 11205133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease.
    Yamashita H; Matsumoto M
    Regen Med; 2007 Jul; 2(4):447-55. PubMed ID: 17635051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease.
    Franke SK; van Kesteren RE; Hofman S; Wubben JA; Smit AB; Philippens IH
    Neurodegener Dis; 2016; 16(5-6):293-303. PubMed ID: 26999593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease.
    Kim YJ; Jeon J; Shin J; Kim NY; Hong JH; Oh JM; Hong S; Kim YJ; Kim YE; Kang SY; Ma HI; Lee U; Yoon J
    Mov Disord; 2017 Aug; 32(8):1211-1220. PubMed ID: 28548297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial Parkinson's disease: a hint to elucidate the mechanisms of nigral degeneration.
    Hattori N; Kobayashi H; Sasaki-Hatano Y; Sato K; Mizuno Y
    J Neurol; 2003 Oct; 250 Suppl 3():III2-10. PubMed ID: 14579118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.
    El-Gamal M; Salama M; Collins-Praino LE; Baetu I; Fathalla AM; Soliman AM; Mohamed W; Moustafa AA
    Neurotox Res; 2021 Jun; 39(3):897-923. PubMed ID: 33765237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in cytokines and neurotrophins in Parkinson's disease.
    Nagatsu T; Mogi M; Ichinose H; Togari A
    J Neural Transm Suppl; 2000; (60):277-90. PubMed ID: 11205147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
    Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
    Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling neurodegenerative diseases in vivo review.
    von Bohlen Und Halbach O
    Neurodegener Dis; 2005; 2(6):313-20. PubMed ID: 16909014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the pathogenetic mechanisms underlying Parkinson's disease in medaka fish.
    Matsui H; Uemura N; Yamakado H; Takeda S; Takahashi R
    J Parkinsons Dis; 2014; 4(2):301-10. PubMed ID: 24366926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
    Shimo Y; Takanashi M; Ohta S; Terashima K; Mori H; Shirai T; Miwa H; Mizuno Y
    No To Shinkei; 2001 May; 53(5):495-505. PubMed ID: 11428377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A guide to neurotoxic animal models of Parkinson's disease.
    Tieu K
    Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a009316. PubMed ID: 22229125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.
    Chen ML; Wu RM
    J Biomed Sci; 2018 Jun; 25(1):52. PubMed ID: 29903014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
    Konno T; Siuda J; Wszolek ZK
    Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of the MPTP-Treated Mouse as a Model for Parkinson's Disease.
    Klemann CJHM; Martens GJM; Poelmans G; Visser JE
    Mol Neurobiol; 2016 Apr; 53(3):1625-1636. PubMed ID: 25676140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.